MedTrace Logo

PI-88 in Hepatocellular Carcinoma After Hepatectomy

NCT00247728 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2022-06-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

PI-88

Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks

Sponsors & Collaborators

  • Medigen Biotechnology Corporation

    collaborator INDUSTRY

  • Cellxpert Biotechnology Corp.

    lead INDUSTRY

Principal Investigators

  • Pei-Jer Chen, MD, PhD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00247728 on ClinicalTrials.gov